HomeNewsTalzenna Permitted for Germline BRCA-Mutated, HER2-Adverse Breast Most cancers
Posted in News on 17th October 2018

October 16, 2018

Talazoparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes

Talazoparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes

The Food and Drug Administration (FDA) has approved Talzenna (talazoparib; Pfizer) for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2‑negative locally advanced or metastatic breast cancer. Concurrently, the FDA has approved Myriad Genetic Laboratories’ BRACAnalysis CDx test as a diagnostic companion to identify patients with breast cancer who are eligible for treatment with Talzenna. 

Talzenna, a poly (ADP-ribose) polymerase (PARP) inhibitor, was evaluated in EMBRACA, an open-label trial that randomized patients with gBRCAm HER2-negative locally advanced or metastatic breast cancer (N=431) to receive talazoparib 1mg or physician’s choice of chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine). Patients received no more than 3 prior cytotoxic chemotherapy regimens for their metastatic or locally advanced disease. In addition, patients were required to have received treatment with an anthracycline and/or a taxane (unless contraindicated) in the neoadjuvant, adjuvant, and/or metastatic treatment setting.

Related Articles

The major efficacy outcome measure was progression-free survival (PFS) evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as assessed by blinded independent central review. The estimated median PFS was 8.6 months in the talazoparib arm vs.5.6 months in the chemotherapy arm (hazard ratio [HR] 0.54, 95% CI, 0.41, 0.71; P <.0001). Fatigue, anemia, nausea, neutropenia, headache, thrombocytopenia, vomiting, alopecia, diarrhea, and decreased appetite were the most common adverse reactions associated with therapy. 

Talzenna will be supplied in 0.25mg and 1mg strength capsules in 30-count bottles.

For more information visit Pfizer.com.

Scroll down to see the next article

Related Post for New single-dose antibiotic successfully treats uncomplicated gonorrhea infections

Can a Doctor Be Assessed Punitive Damages for Altering or Destroying Medical Information?
Cheap and efficient drug doesn’t cut back main hostile cardiovascular occasion charges
HHS: Up to date Bodily Exercise Tips for Individuals Launched
Nocdurna Now Accessible for Nocturia On account of Nocturnal Polyuria
New single-dose antibiotic successfully treats uncomplicated gonorrhea infections